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Facteurs de risque de rejet aigu tôt après la greffe hépatique chez l’enfant 
 
 
 
Introduction et but du travail 
 
Un rejet aigu survient chez 50-80% des patients pédiatriques [1,2,16,17,42,50], avec plus de 
80% des rejets survenants dans les premières 4 semaines après la greffe [45]. Des études 
récentes chez des adultes ont pu montrer que le rejet aigu après la greffe hépatique n’est pas 
associé à une survie réduite ni des patients ni des greffons [44,54,59,62], et qu’il est peut-être 
même nécessaire pour le développement d’une tolérance du greffon [37].  
La cause principale de mortalité après la greffe est l’infection (plus d’un tiers), alors que le 
rejet l’est seulement de 5-10% des cas [2,6,8,12,22,48]. Un traitement anti-rejet, donné sans 
que le patient souffre vraiment d’un rejet, peut même limiter la survie du greffon [59]. 
Pour une greffe réussie il est très important de trouver l’intensité de l’immuno-suppression 
adaptée à chaque patient, avec le but d’éviter d’un côté une immunosuppression trop forte et 
son risque d’infection potentiellement mortelle ou d’autres effets secondaires toxiques et 
autrement une immunosuppression trop faible, lié au risque d’un rejet non contrôlable. 
Jusqu’à maintenant tous les patients traités dans chaque centre reçoivent normalement le 
même traitement immunosuppresseur initial après la greffe, sans tenir compte du risque 
individuel de développer un rejet.  
 
Des études récentes chez des adultes ont pu identifier certains facteurs de risques de rejet 
aigu, comme la maladie de base, le type d’immunosuppression, l’âge du receveur et du 
donneur, l’état général du receveur avant la greffe, le taux sanguin de l’ AST avant la greffe, 
la durée de l’ischémie froide et le HLA-DR miss-match [8,23,41,44,59,61]. Mais les résultats 
des adultes ne peuvent pas être appliqués chez les enfants, à cause des differentes maladies de 
base, la croissance et la maturation de leur système immunologique. 
Jusqu’à maintenant il y a peu de données sur les facteurs de risque de rejet aigu chez l’enfant, 
et les résultats sont contradictoires [16,42,50]. 
 
Le but de ce travail était de chercher des facteurs de risque de rejet aigu chez un groupe de 38 
enfant qui ont reçu une greffe hépatique à l’HUG entre juillet 1989 et janvier 2000. 
 
 
 
Hypothèse 
 
Les facteurs suivants pourraient avoir une influence sur le risque de rejet aigu : 
- Variables du receveur Age, sexe, groupe sanguin, maladie de base, état nutritionnel, 
quantité des leucocytes, eosinophiles et lymphocytes, taux des 
transaminases, gammaglutamyltransferase, bilirubine et 
infection avec CMV/EBV avant la greffe 
- Variables du donneur Age, sexe, présence d’ IgG contre CMV 
- Variables chirurgicales Préparation et durée de l’ischémie du greffon, taux maximal des 
transaminases après la greffe  
- Immunosuppression Intensité de l’immunosuppression, mesurée par les taux de la 
ciclosporine 
 
     
  3 
Patients et Méthodes 
 
Patients  Entre Juillet 1989 et Janvier 2000, 38 enfants ont reçu 42 greffes hépatiques à 
l’Hôpital Universitaire des Enfants à Genève, 18 garçons et 20 filles. 35 des 38 patients sont 
toujours en vie, avec un taux de survie de 92.1%, après un suivi moyen de 6.15ans (2.58-
12.05) jusqu’en Juin 2002. Les causes des trois décès étaient une fois une défaillance 
cardiaque suite à une maladie métabolique non diagnostiquée avant la greffe, et deux fois des 
complications vasculaires et infectiologiques. 
 
Maladies de base 
Atrésie des voies biliaires 24  Cholangite sclérosante   2 
Tyrosinémie   2  Abétalipoprotéinémie   1 
Maladie de Wilson  2  Maladie de Crigler Najjar  1 
Déficit en α1-antitrypsine 2  Syndrome d’Alagille   1 
Défaillance hépatique aigue 2  Choléstase intrahép. progress. familiale 1 
 
4 enfants ont eu besoin d’une deuxième greffe, deux à cause d’une non-fonction du premier 
greffon et deux à cause d’un rejet chronique. 
 
Donneurs Tous les greffons venaient d’un donneur cadavérique. C’étaient touts des 
greffes orthotopiques. Les donneurs étaient sélectionnés selon les critères des organisations 
pour la transplantation de la Suisse et de l’Europe. 
 
Thérapie immunosuppresseur La thérapie antirejet initiale était identique chez tous les 
patients, une triple thérapie avec Ciclosporin A (Sandimmun® jusqu’en 1995, Néoral® 
depuis 1995), Azathioprin et Prednisone. En cas de rejet, 3 doses élevées de Solumédrol iv 
étaient données, suivi par une cure de Prednisone de 2 semaines avec des doses dégressives. 
En cas d’un rejet résistant au Solumédrol, des thérapies avec OKT3, ATG ou Tacrolimus 
étaient choisies. 
 
Définition du rejet Le rejet était diagnostiqué sur la base de signes cliniques, d’une 
élévation des transaminases et de la GGT et d’une biopsie hépatique. L’image histologique du 
rejet était jugée selon la classification de Snover jusqu’en 1996, puis selon la classification de 
Banff. 
Le rejet aigu tôt était défini comme rejet aigu survenant dans les quatre premières semaines 
après la greffe.  
 
Statistique Cette étude est une étude de cohorte rétrospective. Les variables quantitatives 
sont exprimées comme moyenne/ déviation standard ou mediane/min-max. et sont comparées 
avec le « Wilcoxon rank sum » test. Les variables non parametriques sont comparées avec le 
« chi square » test. L’influence des différentes variables sur le  rejet était analysée avec une 
régression logistique et plusieurs modèles d’arbres de classification. Pour évaluer l’effet de 
l’immunosuppression sur le rejet aigu, 10 paires d’enfants, avec et sans rejet, étaient analysées 
et comparées. Une valeur du p<0.05 est considerée comme statistiquement significative. 
L’analyse statistique était fait avec le programme SPSS ( Statistical Package for Social 
Sciences), version 10.0 pour Windows. 
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Résultats 
 
24 enfants des 37 ont eu un rejet aigu (= 64.9%), avec un délai médian de 8 jours (4-30j) 
après la greffe. Pour les analyses suivantes les 24 enfants avec rejet aigu forment le groupe R 
(rejet), les 13 enfants sans rejet le groupe NR (non rejet). 
Pour l’analyse de toutes les variables testées, voir pages 11 et 12 de la thèse. Dans le tableau 
suivant seulement les résultats les plus relevants sont décrits. 
 
Variables  Groupe R Groupe NR Valeur du 
p 
Age à la greffe (m) Mediane /min-max 17.5 (5.5-159) 25 (9-169)  
 Moyenne/ ds 45.25 (50.1) 62.84 (62.53) 0.23 
     
Maladie hépatique Atrésie des voies 
bil. 
14 (58%) 10 (76.9%)  
 Autres 10 3 0.25 
     
Z-score poids Mediane/ min-max - 0.8 (-4.9-1.5) - 2.3 (-7.1-0.8)  
 Moyenne/ds - 1.24 (1.5) - 2.7 (1.9) 0.022* 
     
Z-score taille Mediane/ min-max - 0.9 (-5.3-2.2) -2.15 (-4.9-1.4)  
 Moyenne/ ds -1.02 (1.7) -2.53 (1.8) 0.02* 
     
Leucocytes x109/L Mediane/ min-max 9500 (3000-
28900) 
5850 (2400-
25000) 
 
 Moyenne/ ds 11752 (7675) 7625 (5948) 0.05* 
     
Lymphocytes x109/L Mediane/ min-max 3140 (10-15112) 2208 (640-6000)  
 Moyenne/ ds 3682 (3606) 2316 (1619) 0.34 
     
Eosinophiles x109/L Mediane/ min-max 170 (0-2945) 165 (0-320)  
 Moyenne 398 (643) 161 (114) 0.39 
     
GGT(IU/L) av.greffe Mediane/ min-max 100 (11-1174) 232 (18-471)  
 Moyenne 222 (283.8) 233 (142.2) 0.19 
     
Bili dir. (µmol/L) av. 
greffe 
Mediane/ min-max 154 (0-528) 263.5 (0-606)  
 Moyenne/ ds 159.6 (136.9) 246.5 (180.2) 0.12 
 
 
Avec les variables de ce tableau une analyse, cherchant des facteurs de risque de rejet aigu 
survenant précocement, a été faite avec une régression logistique. Les résultats sont décrits 
avec un arbre de décision, le schéma est montré ci-dessous. 
 
Les résultats montrent, que les enfants avec un z-score de la taille au-dessous de -1.1 ont un 
risque de rejet aigu seulement dans 45% des cas, lorsque les enfants avec un z-score de la 
taille au-dessus de -1.1 ont un risque de rejet aigu élevé dans 93% des cas. Après la sous-
classification des enfants avec un z-score de la taille de moins de -1.1, un autre groupe 
d’enfants avec un risque de rejet aigu majeur a pu être identifié. Les enfants qui ont un z-score 
de la taille de moins de -1.1, un âge à la greffe au-dessous de 17mois et un taux de la GGT 
dans le sérum au-dessous 200 IU/L  ont un risque de rejet aigu de 100%, lorsque les enfants 
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avec un z-score de la taille au-dessous de -1.1, mais un âge à la greffe au-dessus de 17 mois 
ont un risque de rejet aigu faible de seulement 20%. 
 
Arbre de classification avec les variables : z-score pour taille, âge à la greffe et GGT avant la 
greffe 
 
 
 
Traitement immunosuppresseur Dix paires d’enfants, 10 enfants avec et 10 sans rejet 
aigu, identiques pour l’âge et le sexe, sont comparées regardant leurs taux de Ciclosporine 
pendant la période avant le premier rejet aigu de l’un des deux enfants de la paire.  
 
Taux de Ciclosporine 
 
10 Enfants avec rejet (R) 10 Enfants sans rejet (NR) 
Moyenne ( ds ) 261.6 µg/L  (39) 239.5 µg/L (38) 
Médian (min-max)    p = 0.3 246.7 µg/L ( 220-326 ) 232.1 µg/L (168-303) 
 
 
Chez les enfants sans rejet  (groupe NR) la moyenne des taux de la Ciclosporine avait la 
tendance d’être plus basse que chez les enfants avec rejet (groupe R), mais la différence n’est 
pas significative. 
 
 
 
Discussion 
L’incidence du rejet aigu (65%) et la distribution des maladies de base (atrésie des voies 
biliaires extrahépatique 67.3%, maladies métabolique 21.6 %, hépatite fulminante 5.2%) dans 
notre collectif d’enfants sont comparables aux chiffres d’autres centres [1,17,30,34,42,50, 53]. 
 
 
 
 
Z-score height <   - 1.1 
Age at LT <  17.5 m Z – score height <   0.3 
GGT before LT <  200 
Yes No 
R=0.45 R =0.93 
Z-score height <  - 3.75 
R = 1. 0 R = 0.8R = 0.7 R = 0.2
R = 0.4 R = 0.2 R = 0.2R = 1.0 
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Influence des différentes variables sur le risque de rejet aigu survenant tôt  
 
Age: Dans notre collectif d’enfants le rejet aigu était plus fréquent chez les plus jeunes avec 
une fréquence de 80% chez ceux au-dessous de 1 an, comparé à seulement 59% chez les 
enfants au-dessus de 1 an, mais la différence n’était pas statistiquement significative.  Les 
résultats des autres études pédiatriques sont contradictoires : plusieurs auteurs ont fait la 
même observation que nous [16, 56], mais d’autres décrivent un rejet aigu plus fréquent chez 
les enfant plus âgés [6, 25, 42].  Malheureusement l’influence  d’autres facteurs de risque 
potentiels comme l’état nutritionnel et la maladie de base, ne sont pas bien décrits dans ces 
études. Les enfants au-dessous de 1 an sont plus fréquemment greffés pour une atrésie des 
voies biliaires et ont souvent un état nutritionnel moins bon que les plus âgés [30]. 
 
Maladie de base: Des études chez les adultes [4,8, 26, 44, 45] ont pu démontrer que les 
patients souffrant d’une maladie hépatique choléstatique ou autoimmune ont un risque de rejet 
aigu significativement plus élevé, en comparaison de ceux souffrant d’une autre maladie de 
base. Mais ces résultats ne sont pas applicables aux enfants, parce qu’ils souffrent d’un autre 
spectre de maladies que les adultes. 
La cholestase per se, semble avoir un effet protecteur contre le rejet aigu. [3] Chez nos 
patients, 76.9% du groupe NR avaient une atrésie des voies biliaires extrahépatiques comparé 
au groupe R où 58.1% seulement avaient une atrésie. La bilirubine directe avait la tendance 
d’être plus haute chez les enfants sans rejet que chez les enfants avec rejet, p=0.12. Une autre 
étude pédiatrique ne démontrait pas d’ influence de la maladie de base sur le rejet [42]. La 
différence de l’effet de la cholestase entre les adultes et les enfants est peut-être due au fait 
que les hépatopathies cholestatiques chez les adultes sont souvent la conséquence d’une 
maladie autoimmune, alors que c’est plus rarement le cas chez les enfants. 
 
Etat nutritionnel : La plupart des 37 enfants avaient des z-scores pour leur taille et poids au-
dessous de la moyenne des enfants sains, 83% pour le poids et 73% pour la taille. Des z-
scores bas pour le poids et la taille, avaient un effet protecteur significatif contre le rejet aigu. 
Cet effet protecteur de la malnutrition, est aussi observé chez les adultes [26]. La même 
tendance, mais non significative, été observée dans une étude pédiatrique [42]. 
Parce que le z-score de la taille est le facteur le plus significatif pour le risque d’un rejet aigu, 
le modèle statistique l’avait choisi comme première variable dans l’arbre de classification. 
Alors que les enfants avec une malnutrition semblent avoir un risque diminué de rejet aigu, 
mais ont un risque élevé de développer une infection grave, ils pourraient probablement 
profiter d’une immunosuppression plus légère que les enfants en bon état nutritionnel.  
 
Leucocytes : Les leucocytes étaient significativement plus bas chez le groupe NR, mais cette 
variable était directement dépendant du z-score de la taille et du poids dans l’analyse 
statistique avec une régression logistique. Le nombre de leucocytes dépend probablement de 
l’état nutritionnel chez ces patients. 
 
Immunosuppression : Il est généralement accepté, que des taux élevés de ciclosporine 
protègent mieux contre le rejet que des taux bas. Nos résultats étaient contradictoires, car nous 
avons observé des taux de ciclosporine plus hauts chez les enfants avec rejet. Cet effet est 
probablement dû au fait, que la corrélation entre le taux de ciclosporine mesuré avant la 
prochaine dose et le rejet aigu est pauvre. [28] Le Cmax semble être plus significatif que les 
« trough levels » pour la prévention du rejet aigu après la greffe hépatique.[39] Mais il reste 
encore à prouver si un changement de la routine actuelle, de mesurer les « trough levels » de 
la ciclosporine à la mesure des taux correspondants au Cmax, pourra réduire le nombre de 
rejet aigu. 
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Conclusions : Les enfants avec une malnutrition avant la transplantation hépatique et une 
maladie cholestatique ont probablement un moindre risque de rejet aigu que les autres enfants. 
Ils pourraient donc éventuellement profiter d’une immunosuppression plus légère, qui 
limiterait le risque de développer une infection grave.  
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Risk factors for early acute graft rejection in pediatric liver 
transplantation 
 
 
1. Introduction 
 
Liver transplantation (LT) in children has become a "routine" operation during the last ten 
years. Survival rates and outcome have improved a lot. Especially the introduction of potent 
immunosuppressive agents like ciclosporine (CsA) and tacrolimus (Tac) has transformed the 
practice of organ transplantation by reducing considerably rejection rates and therefore 
improving survival of grafts and patients. But also the development of surgical techniques 
adapted to small children and a better understanding of the patho-physiology of transplanted 
children have helped to improve outcome. 
At the University Children's Hospital of Geneva, the pediatric liver transplantation program 
was started in 1989. Since then this hospital is the referral center for all LT in children in 
Switzerland. From July 1989 until January 2000, 38 children underwent 42 LT in Geneva. 
 
Graft rejection is a common and potentially dangerous problem after LT, and may limit graft 
or even patient survival. Acute graft rejection occurs in about 65% of adult patients in the first 
year after LT [61], and in about 50-80% of pediatric patients [1, 2, 16, 17, 42, 50], with over 
80% of the acute rejection episodes occurring within the first 4 weeks after LT [45]. Recent 
studies in adults show, that acute rejection is not related with worse survival rates of patients 
or grafts after LT [44, 54, 59, 62]. It may even be necessary to develop long term tolerance of 
the graft [37]. 
It is also known that the main cause of death after LT in adults and children is infection, 
accounting for about a third or more of the mortality, whereas rejection accounts only for 
about 5-10% of deaths after  LT [2, 6, 8, 12, 22, 48]. Additionally, unnecessarily given anti-
rejection treatment may be associated with inferior graft survival [59]. 
It is therefore very important for successful LT to find the adequate level of 
immunosuppression in order to prevent on one side over-immunosuppression with its high 
risk of potentially lethal infection or other side-effects and on the other side under-
immunosuppression with its risk of untreatable rejection. 
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Immunosuppressive therapies are different from one center to the other and studies therefore 
difficult to compare. However, within a given center, all patients usually receive the same 
immunosuppressive regimen, because they are all considered to be at the same risk of 
rejection.  
Recent studies in adults found several factors influencing the risk for acute graft rejection as 
underlying liver disease, type of immunosuppressive regimen, age of recipient and donor, 
health status of recipient before LT, AST levels before LT, cold ischemia time and HLA DR 
miss-match [8, 23, 41, 44, 59, 61]. But the results of adult studies cannot be used to predict 
outcome after LT in children, because children are very different from adults for example 
regarding their liver pathology, their unique physiology of growth and their maturating 
immune system.  
Only a few studies are analyzing possible risk factors for acute graft rejection in children and 
the results are contradictory [16, 42, 50]. 
 
More data are needed to define risk factors for acute graft rejection after liver transplantation 
in a pediatric population in order to be able to adapt the immunosuppressive therapy to each 
patients individual need and therefore prevent unnecessary side effects, especially potential 
lethal infection, from over-immunosuppression or graft loss from under-immunosuppression.  
 
 
 
2. Aim 
 
The aim of this study is to identify prognostic risk factors for early acute graft rejection  
(EAR) in a group of 38 children who underwent LT at the Geneva University Children's 
Hospital.  
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3. Hypothesis 
 
Various factors like certain features of the patient, the donor, surgical technique and 
immunosuppressive therapy may play a role as risk factors for EAR. 
The following factors will be analyzed for their possible influence on graft rejection: 
 
 
Patient variables: Age 
   Gender 
   Blood group 
Cytomegalovirus (CMV) and Ebstein Barr Virus (EBV) infection 
before transplantation 
   Underlying liver disease 
   Nutritional status before LT 
White blood cell count (number of leucocytes, lymphocytes and 
eosinophils) before LT 
   Serum levels of transaminases, gammaglutamyltransferase and bilirubin  
before LT 
 
Donor properties: Age 
   Gender 
   Previous CMV infection 
 
Surgical factors: Preparation of the graft 
   Duration of cold and warm ischemia time 
   Serum transaminase peak levels after LT (reflecting graft injury) 
 
Immunosuppression: Intensity of immunosuppressive therapy, defined by the range 
    of ciclosporine trough levels  
 
 
 
 
 
  11 
4. Patients and Methods 
 
 
Patients
From July 1989 until January 2000, 38 children underwent 42 liver (LT) at the University 
Children's Hospital of Geneva, 18 boys and 20 girls. The patients were referred to Geneva 
from all over Switzerland, since Geneva is the only LT center for children in Switzerland. All 
transplantations were done with allogeneic grafts from cadaveric donors. 
 
35 of 38 children survived which results in a survival rate of 92.1% with a mean follow-up 
until June 2002 of 6.15 years (2.58-12.05y). 
 
Causes of the 3 deaths: 
One girl died within 24h after LT because of myocardial failure. She needed LT for fulminant 
liver failure, probably due to an underlying multiorganic metabolic disease, unknown prior to 
LT. Because she didn't live long enough to develop rejection she will be excluded from 
further analysis. The two other children, one girl and one boy, died because of vascular and 
infectious problems, 1month and 3months after LT. None died because of rejection. 
 
The underlying diseases leading to transplantation are listed below. 
Underlying disease leading LT: (n=38) 
Extrahepatic biliary atresia  24 (= 63.1%) 
Tyrosinemia    2 
Wilson's disease    2 
Alpha 1antitrypsin deficiency  2 
Fulminant liver failure   2 
Sclerosing cholangitis   2 
Abetalipoproteinemia   1 
Chrigler Najjar's disease   1 
Alagille syndrome   1 
Byler's disease (PFIC)   1 
 
4 of the 38 children (10.5%) needed a second LT. Two children needed a second LT because 
of primary non-function of their first graft on the 3rd and 4th postoperative day. For these two 
children analysis for rejection is done only after their second LT, because time after the first 
LT was too short to develop rejection. 
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The other two re-transplantations had to be done for two girls with chronic graft rejection, six 
and 9 months after their first LT. For these two children analysis was done for the period after 
the first LT. 
 
Donors 
All grafts were taken from cadaveric donors. Donors were selected and controlled according 
to the Swiss and European Transplantation guidelines. Liver from a living related donor was 
not yet used.  
 
Surgical factors 
The decision to take a whole, reduced size or split liver graft depended on the size of the 
donor liver and the size of the abdominal cavity of the recipient. All LT were orthotopic 
transplantations. No auxiliary graft was done. 
 
Immunosuppressive therapy 
Cyclosporin A (CsA) has been used as an immunosuppressive agent after organ 
transplantation for almost 20 years. CsA is a cyclic peptide of fungal origin that through its 
mode of action plays a major role in the prevention of T-cell activation, interleukin 2 
production, and subsequent allograft rejection.  
The bioavailability of CsA displays a considerable inter- and intra-patient variability. The 
bioavailability of the orally administrated drug ranges from 10% to 57% and increases with 
time.  In infants and children CsA absorption is reduced most likely because of the smaller 
absorptive surface area in the pediatric intestine and more rapid bowel transit times. In 
addition pediatric patients may have also more rapid drug clearance because of increased gut 
and hepatic cytochrome P450 enzyme activity. Cytochrome P450 enhances CsA degradation 
in the liver and therefore lowers CsA levels in the blood. For these reasons children usually 
require a much higher dose of CsA to maintain blood levels equivalent to those seen in adult 
counterparts. This is a critical observation because children are believed to mount much 
stronger alloimmune responses than adults and therefore experience more intense allograft 
rejection episodes. [2] 
Variability of bioavailability and bad intestinal absorption of CsA in children, implicate a 
close monitoring of CsA levels especially during the first weeks after LT.  
The CsA-levels fluctuate often enormously and drug doses therefore have to be adjusted to 
keep the patient in the therapeutic target range. This drug dose adaptation is essential, because 
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too low CsA blood levels are a potential risk for graft rejection and too high levels can lead to 
toxic side effects as nephrotoxicity, hepatotoxicity, central nervous system toxicity and severe 
infections. 
 
CsA formulation and blood level monitoring 
Since the first LT in 1989, CsA formulation for oral application and analysis methods to 
monitor CsA blood levels have changed. 
 
CsA formulation 
From 1989 to 1995 CsA was used under the trade name of Sandimmun®. This formulation 
was extremely lipophilic and its intestinal absorption therefore much dependant of an 
adequate bile flow and lipid digestion. In order to improve intestinal absorption resulting in 
better bioavailability, CsA was transformed into a microemulsion formula with better 
hydrophilic qualities. Its new trade name is Neoral®. Neoral was introduced on the market in 
1995 and replaced the old formulation in the same year. 
Therefore all children undergoing LT from 1989 - 1995 (n = 15) were treated with 
Sandimmun®, after 1995 (n = 22) they received Neoral®. 
 
CsA blood level monitoring methods 
At the beginning of CsA use the methods to measure the drug's blood level were less precise 
and less specific than they are today, because CsA was measured together with its non active 
metabolites ( = polyclonal CsA levels). During our observation period the biochemical 
analysis method was changed twice, first in 1990 and a second time in 1995.  
1989-90 The lab method available before 1990 allowed to measure polyclonal CsA 
  levels only and was therefore quite unspecific. For this reason the first 3  
  children monitored with this method were not included when comparing blood 
   levels of CsA of children with and without rejection. 
1990-95 The next method used, was developed by Abbott laboratories ("Abbott" 
method), and measured poly- and monoclonal CsA levels. This method was 
introduced at the University Hospital of Geneva in 1990. 12 children were 
monitored with this method from 1990 until 1995. 
1996-now In May 1996 the "Abbott" method was replaced by "SIVA" method, a more 
  specific technique which measures only active CsA in blood and none of its 
  inactive metabolites. 
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The better specificity of "SIVA" method leads to around 30% lower CsA blood 
levels compared to the "Abbott" method. Unfortunately inter- and intra-
individual variations of CSA blood levels are too important to allow a precise 
transformation of the values from one method to the other. So the blood levels 
of this two latter techniques cannot be compared directly and the 12 children 
transplanted before 1996 have to be analyzed separately from the 22 children 
transplanted after 1996 when comparing CsA blood levels between children 
with and without rejection. 
   
Because of the higher specificity of "SIVA"-method, target CsA trough levels to obtain an 
efficient immunosuppression are lower when measured with "SIVA" than with "Abbott"-
method. The CSA trough level aimed for with "SIVA"-method was 270 µg/l (±20) and  the 
blood level aimed for with "Abbott"-method 320 µg/l (±20). 
 
    LT 1991-95   LT 1996-99   
    n = 12    n = 22  
CsA formulation  Sandimmun®   Neoral® 
CsA monitoring method "Abbott"   "SIVA" 
 
CsA blood levels were always measured before the next dose (trough levels) and dose 
adjustments were made daily or as needed, to reach the aimed target level. During the first 2-3 
weeks post LT, CsA levels were generally measured once to twice daily and only when the 
levels were stable the control intervals were spaced. 
 
Immunosuppressive therapy was always started intra-operatively with intravenous steroids 
and ciclosporine, afterwards complemented by azathioprine on the first day according to the 
numbers of lymphocytes. Steroids and ciclosporine were given per mouth as soon as tolerated 
by the patients gastrointestinal function, most often within the first week after LT.  
 
Salvage therapy in case of rejection was done with a triple course of high dose steroids, 
followed by a gradual reduction over 2 weeks. 
Children with rejection episodes not responding to steroids, were treated by adding OKT3 or 
ATG or were switched from CsA to Tac. 
Definition of rejection
Rejection is defined as damage or destruction to a graft by an allogeneic recipient's immune 
system. It may lead to graft dysfunction or even graft loss. Rejection is characterized by a 
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combination of clinical, biochemical and particularly histological features. Histology is 
usually considered as the gold standard for the diagnosis of rejection. 
There are several forms of liver allograft rejection, which can be differentiated by clinical and 
histological features. Because the precise pathogenic mechanisms are not all known, 
terminology relies on descriptive features and is thus imprecise and often inconsistent. The 
several forms of liver allograft rejection are commonly classified as: 
 
- Fulminant acute rejection (massive hemorrhagic necrosis) 
- Acute cellular rejection 
- Ductopenic rejection (vanishing bile duct syndrome) 
- Chronic vascular rejection 
 
The terminology and definition of liver allograft rejection has emerged from consensus 
discussions and studies by different groups. Although there is now agreement about the 
definitions of the histological patterns of acute allograft rejection, controversy remains as to 
the diagnostic, and particularly prognostic, significance of many of the features. The 
difficulties are that definitions are largely empirical and derived from observations made in 
different centers, employing a wide range of immunosuppressive treatment protocols that may 
modify the development of rejection. Furthermore, the histological features of rejection will 
vary with time and few classifications have taken into account the dynamic progression of 
histological damage. Finally, the concomitant presence of other pathologies, such as 
preservation damage, graft ischemia, infection or drug toxicity, may modify, mask or mimic 
some features of rejection. 
Acute cellular rejection usually occurs early after transplantation and is defined by the 
histological triad of portal inflammation, bile duct damage and venous endothelial 
inflammation [32]. In centers where biopsies are routinely taken at the end of the first post-
transplant week, these histological features are seen in up to 80% of patients [33].  
However, clinically apparent rejection ( defined as a change of blood and liver parameters 
with or without fever) is seen only in approximately 50-60% of patients. 
 
In the Geneva protocol, routine liver biopsy after LT was not done. When rejection was 
suspected from clinical signs (fever) and biochemical features (rising alcaline phosphatase, γ-
glutamintransferase, transaminases and bilirubin), liver biopsy was done to confirm rejection. 
Some of the patients were too unstable or would have needed extra anesthesia for liver 
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biopsy. They were treated for rejection on the basis of clinical and biochemical signs only. 
Only children with clinically relevant rejection were treated. No patient was treated with 
OKT3, ATG or switched to Tac without histologically proven rejection. 
 
As described above, definition and grading of histological rejection changed over the past ten 
years. Up to 1996 the classification system of Snover [57] was used in Geneva University 
Hospital, in 1997 it was replaced by the Banff classification [18]. 
 
Most acute rejection episodes occur within 4 weeks of transplantation [45].  
In this study only risk factors for early acute rejection (EAR), defined as rejection within 4 
weeks of LT are examined.  
The day of appearance of EAR was defined as the post-LT day on which clinical signs and the 
impairment of liver function tests led to performing a diagnostic liver biopsy and to starting 
salvage treatment. 
 
 
Statistical analysis
This study is a retrospective cohort study. 
Quantitative variables are expressed as median/ range and mean/standard deviation and are 
compared between groups by the Wilcoxon rank sum test. Categorical variables are compared 
with the chi square test. The influence of various variables on EAR was analyzed with logistic 
regression analysis and different models of classifications trees, validating the results with the 
ROC values.  
To compare CsA levels of children with and without EAR, 10 pairs of children matched for 
age, sex, CsA formula and CsA measuring methods were analyzed. 
P value < 0.05 indicates statistical significance in all analyses. 
Statistical analysis was performed using the Statistical Package for Social Sciences, version 
10.0 for Windows (SPSS Inc. Chicago IL) statistical software. 
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5. Results 
 
5.1. Rejection 
No patient in this group of children had hyperacute rejection.  
Of the 37 study patients, 24 patients (64.9 %) had EAR, requiring treatment. 16 patients had 
one episode of rejection, 7 had two and 1 had three episodes of  EAR. The median time of 
appearance of EAR after LT was 8 days (4-30d). 
Rejection was diagnosed from clinical and biochemical signs alone in 8 patients and 
confirmed by liver biopsy and histology in the other 16 patients. 18 of the 24 patients with 
EAR (75%) responded to treatment with steroid salvage therapy. Of the other 6 children who 
didn't respond to steroids, two were treated with OKT 3, one additionally with ATG, and 4 
were switched from CsA to Tac. 
6 patients had late acute rejection, with a mean follow-up of 5.4 years (1.83-11.3y) for all 37 
patients. Four of these six patients had their first EAR already within the first month after LT, 
only two had their first acute rejection after the first month after LT.  
Two girls (5.4%) had chronic rejection, unresponsive to treatment with Tac. They needed re-
transplantation 6 and 9 months after the first LT. Both of them had to be treated for two 
episodes of  EAR.  
 
Figure 1 below shows an overview of all types of rejection occurring in this cohort. 
All patients: n = 37 
☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺☺ 
          
EAR: n = 24 
☻☻☻☻☻☻☻☻☻☻☻☻☻☻☻☻☻☻☻☻☻☻☻☻ 
   
Late acute rejection: n = 6 
☻☻☻☻        ☺☺ 
 
Chronic rejection: n = 2 
☻☻ 
Fig. 1 
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The 24 children with EAR will be referred to as group R (rejection), the 13 children without 
EAR as group NR (no rejection). 
 
 
5.2. Patient (host) variables 
 
Tab 1 summarizes the results of the comparison of all patient variables of the children who 
had EAR (group R) with the children without EAR (group NR). 
 
Table 1 
Features  Group R Group NR p-value 
Host     
Age at LT in months Median (min-max) 17.5 (5.5-159) 25 (9-169) 
 Mean (± sd) 45.25 ( 50.1) 62.84 ( 62.53) 0.23 
     
Gender Male 11 7 
 Female 13 6 0.64 
     
Blood group A 13 5  
 O 10 8  
 B 1  0.63 
     
CMV-status (IgG-Ab) Pos 13 6 
 Neg 8 5  
 Unknown 3 2 0.68 
     
EBV-status (IgG-Ab) Pos 11 7 
 Neg 10 4 
 Unknown 3 2 0.54 
     
Underlying liver disease EHBA 14 (58.1%) 10 (76.9%) 
 Other 10 (41.9%) 3 (23.1%) 0.25 
     
Weight in kg Median 10.5 (5.9-53) 9 (5.7-57.3)  
 Mean  15.0 ( 11.04 ) 16.7 ( 14.7 )  0.8 
     
Z score weight Median -0.8 (-4.9-1.5) -2.3 (-7.1-0.8)  
 Mean -1.24 (1.5) -2.7 (1.9) 0.022* 
     
Height in cm Median 78.25 (62-173) 75.75 (65-174.5)  
 Mean 92.21 (31.05) 97.08 (35.42 0.92 
     
Z score height Median -0.9 (-5.3-2.2) -2.15 (-4.9-1.4)  
 Mean -1.02 (1.7) -2.53 (1.8) 0.02* 
     
Z score weight/ height Median -0.4 (-1.8-0.8) -0.55 (-3.3-1.3)  
 Mean -0.45 (0.7) -0.63 (1.07) 0.6 
     
Leucocytes (x109/L) Median 9500(3000-28900) 5850(2400-25000)  
 Mean 11752 (7675) 7625 (5948) 0.05* 
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Lymphocytes (x109/L) Median 3140 (10-15112) 2208 (640-6000)  
 Mean 3682 (3606) 2316 (1619) 0.34 
     
Eosinophiles (x109/L) Median 170 (0-2945) 165 (0-320)  
 Mean 398 (643) 161 (114) 0.39 
     
AST (IU/L) before Tx Median 196 (46-3542) 278 (27-1326)  
 Mean 361 (707.3) 343.1 (343.8) 0.48 
     
ALT (IU/L) before Tx Median 68 (24-5137) 91 (31-672)  
 Mean 332 (1050.5) 182.5 (196.6) 0.52 
     
GGT (IU/L) before Tx Median 100 (11-1174) 232 (18-471)  
 Mean 222.2 (283.8) 233.8 ( 142.2) 0.19 
     
Bili tot (µmol/L) before 
Tx 
Median 262 (11-642) 331.5 (9-744)  
 Mean  253.9 (186.9) 339.9 (241.0) 0.33 
     
Bili dir (µmol/L) before 
Tx 
Median 154 (0-528) 263.5 (0-606)  
 Mean 159.6 (136.9) 246.5 (180.2) 0.12 
     
Follow-up in y (03/2001) Median 4.7 (1.33-10.8) 3.58 (1.4-10.5)  
 Mean 5.06 (3.9) 4.78 (4.07) 0.77 
     
 
 
Age  
The mean age (in months) at transplantation of all children was 50.7 (±53.9 sd), median 
22.5 (5.5 - 169), see figure 2, age at transplantation, below. 
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Figure 2 
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The children with EAR (group R) tended to be younger with a mean age at LT of 45.2 months 
(±50.1 sd), median 17.5 (5.5-159), compared with 62.8 months (±62.53sd), median 25 (9-169) 
in group NR, but the difference was not significant. (p=0.23) 
 
Age at LT (in months)  Whole group  Group R  Group NR 
Mean (±sd)   50.7 (53.9)  45.25 (50.1)  62.8 (62.5) 
Median (min-max)  22.5 (5.5-169)  17.5 (5.5-159)  25 (9-169) 
P = 0.23 
Table 2 
 
10 of the 37 children were younger than 1 year. In this group of children younger than 1 year, 
8 out of 10 (80%) had EAR, compared with only 16 out of 27 (59%) children older than 1 
year, but the difference was not significant with a p-value of 0.2. 
 
 
Gender 
In the whole group of 37 children there were 18 boys and 19 girls. No difference of sex 
distribution was found between the 2 groups, 11 boys and 13 girls in group R and 7 boys and 
6 girls in group NR. (p=0.64) 
 
 
Blood group 
All 37 patients had liver grafts from donors with identical blood group, 18 had blood group A, 
18 group O and 1 group B. In group R 13 children had blood group A, 10 had O and 1 B. In 
group NR 5 children had blood group A and 8 had O, which was not significantly different. 
 
Blood group   Whole group  Group R  Group NR 
A    18    13   5 
O    18   10   8 
B    1   1   0 
P = 0.63 
Table 3 
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CMV and EBV infection before LT 
CMV and EBV IgG antibody-status before LT was known only for 32 of the 37 children. 
Table 4 below shows the results of the whole group, group R and NR. There was no 
difference regarding CMV and EBV infection before LT between the two groups. 
 
CMV infection before LT Whole group  Group R  Group NR 
Positive    19   13 (54%)  6 (46%) 
Negative   13   8   5 
Unknown   5   3   2 
P = 0.68 
 
EBV infection before LT 
Positive    18   11 (45%)  7 ( 53%) 
Negative   14   10   4 
Unknown   5   3   2 
P = 0.54 
Table 4 
 
 
Underlying liver disease 
24 of 37 children (67.3%) were transplanted for extrahepatic biliary atresia (EHBA), and 4 
(10.8%) for other cholestatic liver diseases, 1 with Alagille syndrome, 1 with progressive 
familial intrahepatic cholestasis (PFIC) and 2 children because of sclerosing cholangitis.  
8 children had LT for different metabolic diseases (21.6%), tyrosinemia 2, Wilson's disease 2, 
α1-antitrypsin deficiency 2, Crigler Najjar 1 and abetalipoproteinemia 1. One child had LT 
for acute liver failure after intoxication with Amanita Phalloides  
 
 Underlying liver disease (n=37)
Extrahep. biliary atresia
Other cholestatic diseases
Metabolic diseases
Fulminant hepatitis
 
 
 
 
 
 
 
Figure 3 
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Table 5 below shows the distribution of the underlying liver diseases in the whole group, in 
group R and NR.  
 
Underlying liver disease  Whole group  Group R  Group NR 
Extrahepatic biliary atresia 24   14   10 
Tyrosinemia   2   1   1 
M. Wilson   2   2   0 
α1-Antitrypsin Deficiency 2   1   1 
Crigler-Najjar Disease  1   1   0 
Abetalipoproteinemia  1   0   1 
Sclerosing cholangitis  2   2   0 
Alagille syndrome  1   1   0 
PFIC    1   1   0 
Fulminant hepatitis  1   1   0 
Table 5 
 
 
Figure 4 shows the different origins of the underlying liver diseases in Group R and NR. 
 
  Group R     Group NR 
 
EHBA
Other chol.
Metabolic
Fulm. Hep.
 
Figure 4 
 
There were more children with extrahepatic biliary atresia (EHBA) in group NR, 10 of 13 
(=76.9%) than in group R 14 of 24 (=58.1%), but there was no statistical difference, p=0.25. 
Children with other cholestatic diseases than EHBA were all in group R.  
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Nutritional status before transplantation 
Nutritional status was assessed before LT by measuring:  
- Body weight in kg  
- z-score of weight  
- Height in cm 
- z-score of height 
- z-score of weight/ height 
 
Despite intensive nutritional support for underweight children prior to LT, 31 of the 37 
children (83.7%) had a body weight below the mean for their age, this means a negative z-
score. 27 children (72.9%) were smaller than the mean height for their age. The most 
underweight child was a girl with advanced cirrhosis due to extrahepatic biliary atresia, she 
had to be re-transplanted because of primary failure of her first graft and died after the second 
LT because of vascular and infectious problems, she didn't suffer from rejection. 
The child with the smallest height compared to the mean height for age is a boy with Alagille 
syndrome, a syndrome known to cause small stature. 
 
All the results for weight, height and the respective z-scores for the whole study group, group 
R and NR are listed in table 6 below. 
 
Nutritional status   Whole group  Group R  Group NR 
Weight (kg)  median (min-max) 10.5 (5.7-57.3)  10.5 (5.9-53)  9 (5.7-57.3) 
  mean (sd)  15.62 (12.3)  15 (11.04)  16.7 (14.7) 
  p=0.8 
z-score weight median   -1.8 (-7.1-1.5)  -0.8 (-4.8-1.5)  -2.3 (-7.1-0.8) 
  mean   -1.76 (1.8)  -1.24 (1.5)  -2.7 (1.9) 
  p=0.02* 
Height (cm) median   77.5 (62-174.5)  78.25 (62-173)  75.7 (65-174.5) 
  Mean   93.84 (32.15)  92.21 (31.05)  97.08 (35.42) 
  p=0.9 
z-score height median   -1.45 (-5.3-2.2)  -0.9 (-5.3-2.2)  -2.15 (-4.9-1.4) 
  mean   -1.52 (1.87)  -1.02 (1.7)  -2.53 (1.8) 
  p=0.02* 
z-score w/h median   -0.4 (-3.3-1.3)  -0.4 (-1.8-0.8)  -0.55 (-3.3-1.3) 
  mean    -0.51 (0.86)  -0.45 (0.7)  -0.63 (1.07) 
  p=0.6 
Table 6 
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Weight in kg and height in cm were not significantly different between group R and NR.  
But the z-scores for weight ( -2.7 in group NR versus -1.24 in group R) and height (-2.53 in 
group NR versus -1.02 in group R) were significantly lower for children who did not suffer 
from EAR. 
 
Z scores for weight in group R and NR 
N =
REJECT
W
E
IG
H
TZ
4
2
0
-2
-4
-6
-8
Figure 5 
 
Z scores for heigh
N =
REJEC
H
E
IG
H
TZ
4
2
0
-2
-4
-6
Figure 6 
 Group NR        Group R2413
10
11 p = 0.02* 
t in group R and NR 
TGroup NR Group R2412
10
p = 0.02* 
 25 
Correlation between age at transplantation, underlying liver disease and nutritional status 
Because there was a trend for older age and a higher number of children with EHBA in group 
NR and because children in group NR were more underweight and smaller than children in 
group R, correlations between age at liver transplantation, underlying liver disease and 
nutritional status are examined in this chapter. 
  EHBA   
(n=24) 
Other diseases 
(n=13) 
Age at LT (months) Median (min/max)  17.5 (8-169)  110 (6-168) 
 Mean (±sd) 28.73 (±37.9) 93.35 (±58.0) 
 p = 0.005*   
Weight z-score Median (min/max) - 2.2  (-7.1/+1.5) -1.4 (-4.2/+0.9) 
 Mean (±sd) - 1.97 (±1.99) - 1.38 (±1.5) 
 p = 0.4   
Height z-score Median (min/max) - 1.9 (-4.9/+2.2) - 0.8 (-5.3/+2.0) 
 Mean (±sd) - 1.73 (±1.79) - 1.16 (± 2.0) 
 p = 0.2    
Table 7 
 
Figure 7 below shows the age at transplantation of children with EHBA (red) and with other 
liver diseases (green). 
Underlying liver disease and age at LT
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green = Other diseases 
 
red = Extrahep. biliary atresia 
 
  26 
The children with EHBA had to undergo LT at a significantly younger age (median 
17.5months) than children with other liver diseases (median 110 months), p=0.005. 21 of 24 
children with EHBA (=87%) had LT before the age of 4 years compared with only 4 of 13 
children (30%) with other liver diseases. 
The children with EHBA showed a trend for lower z-scores for weight and height than 
children with other diseases but the difference was not statistically different. 
 
 
White blood cell count 
The numbers of leucocytes, lymphocytes and eosinophils were counted for each patient 
within 24 hours before LT. The results for the whole group, group NR and R are listed in the 
following table. Children with EAR had significantly higher white cell counts than children 
without EAR, p = 0.05. Also the numbers of lymphocytes and eosinophils were higher in 
group R than in group NR, but this difference didn't reach statistical significance. 
 
White cell count    Whole group  Group R  Group NR 
Leucocytes median (min-max) 7900 (2400-28900) 9500 (3000-28900) 5850 (2400-25500) 
(x 109/L) mean (sd)  10337 (7315)  11752 (7675)  7625 (5948) 
  p=0.05* 
Lymphocytes median   3108 (10-15112)  3140 (10-15112)  2208 (640-6000) 
(x 109/L) mean   3227 (3127)  3682 (3606)  2316 (1619) 
  p=0.34 
Eosinophils median   169 (0-2945)  170 (0-2945)  165 (0-320) 
(x 109/L) mean   314 (529)  398 (643)  161 (114) 
  p=0.39 
Table 8 
 
 
Liver tests before transplantation 
Liver tests were determined in the serum for each patient within 24h before LT. The values 
for AST, ALT, GGT, total and direct bilirubin were not significantly different between the 
two groups. The biggest difference was seen for direct bilirubin with a higher value in group 
NR than R. This result corresponds to the higher number of children with EHBA in group 
NR. 
The results for AST, ALT, GGT, total and direct bilirubin are listed in table 9 below. 
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Liver tests before LT   Whole group  Group R  Group NR 
AST IU/L median (min-max) 206 (27-3542)  196 (46-3542)  278 (27-1326) 
  mean (sd)  354.9 (601.7)  361 (707.3)  343.1 (343.8) 
  p=0.48 
ALT IU/L median   90 (24-5137)  68 (24-5137)  91 (31-672) 
  mean   280.7 (855.4)  332 (1050.5)  182.5 (196.6) 
  p=0.52 
GGT IU/L median   163 (11-1174)  100 (11-1174)  232 (18-471) 
  mean   226.2 (242.2)  222.2 (283.8)  233.8 (142.2) 
  p=0.19 
Bili total median   262 (9-744)  262 (11-642)  331.5 (9-744) 
µmol/L  mean   283.4 (207.6)  253.9 (186.9)  339.9 (241.0) 
  p=0.33 
Bili direct median   188 (0-606)  154 (0-528)  263.5 (0-606) 
µmol/l  mean   189.4 (156.1)  159.6 (136.9)  246.5 (180.2) 
  p=0.12 
Table 9 
 
 
Follow-up after LT 
The observation period for all surviving children lasts from the day of LT until the end of 
October 2001. Duration of follow-up was not different between the two groups. 
 
Follow-up after LT   Whole group  Group R  Group NR 
Median (min-max) in years  5.4 (1.83-11.3)  4.8 (1.83-11.3)  5.08 (1.9-11) 
Mean (±sd) in years   5.45 (2.9)  5.56 (2.9)  5.28 (3.07) 
p=0.77 
Table 10 
 
 
5.3. Donor variables 
Variables of the donor as age and gender, gender matching between donor and host, and 
CMV status of the donor are examined as possible risk factors for graft rejection. Table 11 
below shows all results for group R and NR. 
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Donor  Group R Group NR P value 
     
Age in years Median (min/max) 18 (1-55) 16 (0.6-49)  
 Mean (± sd) 19.66 (15.12) 17.43 (11.6) 0.7 
     
Gender male 18 10  
 female 6 3 0.89 
     
Gender host/donor female/female 6 3  
 female/male 7 3  
 male/female 0 0  
 male/male 11 7 0.8 
     
CMV-status (IgG-Ab) pos 10 9  
 neg 13 4 0.13 
Table 11 
 
Age of the donor 
The age of the donor was not different in group R and NR, with a mean of 19.6 years for 
donors in group R versus 17.43 years in group NR (p=0.7). 
Age of donor    Whole group  Group R  Group NR 
Median (min-max) in years  17 (0.6-55)  18 (1-55)  16 (0.6-49) 
Mean (±sd) in years   18.8 (13.87)  19.66(15.12)  17.43 (11.6) 
p=0.7 
Table 12 
 
Gender of the donor 
28 of 37 donors were males (=75.6%). The number of male or female gender of the donor was 
not different between group R and NR. Gender matching between host and donor in group R 
and NR was also not different. No male patient received a graft from a female donor in the 
whole group, by chance all 9 grafts from female donors were given to female recipients.  
 
Gender of donor   Whole group  Group R  Group NR 
Male     28   18   11 
Female     9   6   3 
p=0.89 
Gender-match: host/donor 
Female/female    9   6   3 
Female/male    10   7   3 
Male/female    0   0   0 
Male/male    18   11   7 
p=0.8 
Table 13 
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CMV – status of donor
The status post CMV infection, defined by positive IgG antibodies for cytomegalo virus in 
blood, is known for 36 of the 37 donors. No donor had acute CMV infection at the time of 
transplantation. Only 10 of 23 donors were CMV positive in group R compared to 9 of 13 in 
group NR, but the difference was not statistically different. 
 
CMV-status of donor   Whole group  Group R  Group NR 
CMV IgG antibodies positive  19   10 (43%)  9 (69%)  
CMV IgG antibodies negative  17   13   4 
p=0.13 
Table 14 
 
 
5.4. Surgical variables
Surgical variables as preparation of the graft, duration of cold and warm ischemia time and 
peak AST and ALT levels within 48h after LT are analyzed as possible risk factors for EAR. 
Results for group R and NR are summarized in table 15 below. 
 
Surgical variables  Group R Group NR p-value 
     
Graft Whole liver 7 3  
 Partial liver 15 9  
 Split liver 2 1 0.9 
     
Cold ischemia time Median (min-max) 513 (240-750) 465 (405-750)  
(min) Mean (±sd) 505.26 (137.94 501.1 (100.6) 0.93 
     
Warm ischemia time Median 61 (15-120) 52 (45-82)  
(min) Mean  63.94 (25.75) 59.0 (13.06) 0.64 
     
Peak AST (IU/L) Median 906 (214-8160 789 (285-5292)  
 Mean  1450 (1717.4) 1296.25 (1449.2) 0.67 
     
Peak ALT (IU/L) Median 618 (118-3315) 633 (102-3759)  
 Mean  798.5 (695.2) 924.0 (999.39) 0.98 
Table 15 
 
 
Preparation of the graft 
For the reason of body size miss-match between donor and host, only 10 children could 
receive a whole liver graft. The liver had to be reduced before LT for 24 children, most 
received the left liver lobe. 3 children received a split liver with 1 or 2 segments.  
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There was no difference of graft preparation between group R and NR. 
 
Preparation of the graft   Whole group  Group R  Group NR 
Whole liver    10   7   3 
Reduced liver (mostly left lobe)  24   15   9 
Split liver (one or two segments)  3   2   1 
p=0.9 
Table 16 
 
 
Duration of cold and warm ischemia time 
Cold ischemia time, defined as the time interval between graft removal from the donor and 
beginning of transplantation, including preparation of the graft, is known for 30/37 patients. 
Warm ischemia time, defined as the time from the beginning of graft implantation until the 
completion of all vascular anastomoses, is known for 27/37 patients only. There was no 
difference for cold and warm ischemia time in both groups. 
 
Ischemia time (IT)    Whole group (n=30) Group R  Group NR 
Cold IT   Median (min-max) 495 (240-750)  513 (240-750)  465 (405-750) 
(in minutes) Mean (±sd)  504 (123.7)  505.2 (137.9)  501.1 (100.6) 
  p=0.93 
 
     Whole group (n=27) Group R  Group NR 
Warm IT Median   60 (15-120)  61 (15-120)  52 (45-82) 
(in minutes) Mean    62.2 (22.1)  63.9 (25.7)  59.0 (13.06) 
  p=0.64 
Table 17 
 
 
Transaminase peak levels 
Transaminase blood levels were measured 12 hourly for the first 3-4 days after LT, afterwards 
once daily for at least 2 weeks. Peak levels, defined as the highest levels measured 
postoperatively, were observed within 24 to 48 h after LT. There was no difference between 
the two groups regarding peak levels of AST and ALT within 48 hours after LT. 
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Transaminase peak levels after LT Whole group  Group R  Group NR 
AST IU/L median (min-max) 888 (214-8160)  906 (214-8160)  789 (285-5292) 
  mean (±sd)  1397.3 (1610.4)  1450 (1717.4)  1296.2 (1449) 
  p=0.67 
ALT IU/L median (min-max) 618 (102-3759)  618 (118-3315)  633 (102-3759) 
  mean (±sd)  841.5 (799.7)  798.5 (695.2)  924.0 (999.3) 
  p=0.98 
Table 18 
 
 
5.5. Risk analysis for EAR 
In order to identify independent risk factors for EAR, variables found to be significant, or of 
borderline significance, in the uni-variate analysis were taken as starting points for stepwise 
logistic regression analysis. After that, testing of different models of classification trees, 
without and with crossover validation, was done to assess the risk for EAR according the 
presence or absence of the tested variables. 
 
Only three variables, z-score for weight, z-score for height and numbers of leucocytes were 
statistically different between group R and NR in the uni-variate analysis. But all three 
variables were found to be in correlation with each other by multivariate analysis. This means 
that the most underweight children had also lower z-scores for height and lower leucocyte 
counts before LT.  
Therefore only the variable z-score for height was included in the risk score analysis together 
with the variables: age of the child at LT (p=0.2), GGT serum level before LT (p=0.19) and 
highest AST value post LT (p=0.67). The classification tree models were tested for z-score for 
height alone and in combination with one, two or all three of the other variables. The model 
with the three variables z-score for height, age at LT and GGT before LT gave the best result 
with a ROC () value of 0.917 for the original data and 0.784 after crossover validation. 
  
The results are shown in figure 8 and 9 on the next side.  
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Figure 8 shows the area under the curve of ROC values (with original and cross-validated 
data) for the 4 different tree classification models tested. 
 
Figure 8: AUC ROC, original and cross-validated values for model 1 to 4 
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  Number of patients misclassified with each model: 
5/35  5/35  7/36  7/36 
 
The best model with the highest AUC ROC after cross-validation is model 2 with the 
variables: z-score height, age at LT and GGT before LT. Model 1 with all 4 variables is over-
fitted to the original data and models 3 and 4 give less accurate results than model 2.  
 
Therefore model 2 is chosen as a possible classification tree for estimation of risk of EAR for 
a single patient before LT. The model is explained in figure 9. 
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The variables are all printed in blue color. If the variable fits for a certain patient (yes), the 
risk (R =) or probability of EAR is displayed in the yellow box at the left side and if the 
variable doesn’t fit the risk is displayed in the pink box at the right side of the variable. R=1.0 
means a 100% risk for EAR in all the patients fulfilling the corresponding criteria. 
 
Fig. 9: Classification tree with the variables z-score for height, age at LT and GGT before LT 
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Z-score height <   - 1.1 
Age at LT <  17.5 m Z – score height <   0.3 
GGT before LT <  200 
Yes No 
R = 0.45 R = 0.93
Z-score height <  - 3.75 
R = 1. 0 R = 0.8R = 0.7 R = 0.2
R = 0.4 R = 0.2 R = 0.20 
 R = 1. 
hese results show, that children with a z-score for height below - 1.1 have an overall risk of 
AR of  45%, whereas children with a z-score for height above -1.1 have a high risk of EAR 
f  93%.  
y sub-classifying the group of children with a z-score of height below -1.1, another high risk 
roup for EAR can be identified. Children with a z-score for height below -1.1, age at LT 
elow 17.5m and GGT serum values before LT below 200 IU/L are at a risk for EAR of 
00%, compared to children with a GGT value above 200 IU/L who have a lower risk of only 
0%. Children with a z-score for height below -1.1, but age at LT above 17.5m have only a 
isk of developing EAR of 20%. 
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5.6. Immunosuppressive treatment 
Initially all 37 children were treated with the same immunosuppressive triple therapy with 
steroids, azathioprine and cyclosporine, starting the therapy during LT. Despite the aim to 
obtain the same target trough level for CsA for all children, not all children could always be 
maintained in this range. To find out whether lower CsA trough levels during the first days 
and weeks after LT could be a risk factor for EAR, CsA levels of children in group R and NR 
were compared, analyzing 10 age and sex matched pairs of children.  
Both children of a pair received the same formula of CsA (Sandimmun® or Neoral®) and 
their CsA trough level was measured with the same method (Abott or Siva analysis 
technique). Daily CsA levels were measured and compared from the first day after LT until 
the day when rejection was diagnosed for the child from group R of the pair. The CsA trough 
levels of all ten pairs of children are shown in figure 10 and 11.  
 
 
Comparison of daily CsA trough levels between group R (red) and NR (blue) from LT 
until the first day of rejection 
For the pairs 5 to 10 in figure 10, the CsA trough levels were measured with SIVA method 
and the children were treated with Neoral®.  
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For pairs 1 to 4 in figure 11 below, the CsA trough level was measured with Abbott method 
and the children were treated with Sandimmun®. 
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Figure 11 
 
Table 19 shows the comparison of  the mean CsA trough levels between the 10 matched pairs 
of children with and without EAR.  
   
 10 children from group R 10 children from group NR 
Mean CsA level (± sd) 261.6 µg/L (± 39) 239.5µg/L (± 38) 
Median (min-max) 
p = 0.3 
246.7µg/L (220-326) 232.1µg/L (168-303) 
 
Table 19 
 
The mean CsA trough levels tended to be lower in the 10 children from group NR compared 
with the levels of the 10 children from group R, with a mean/median of the mean in group R 
of 261.6 / 246.7µg/L versus 239.5 / 232.1µg/L in group NR, p=0.3, but the difference was not 
statistically significant. 
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6. Discussion 
 
 
6.1. Incidence and timing of EAR 
 
The number of  EAR, 65% in this cohort of children is comparable to the incidences reported 
in other pediatric studies for patients who had received cadaveric grafts and were treated with 
a comparable triple therapy of steroids, azathioprine and CsA after LT [Alonso 78%, Cox 
74%, Reding 76%]. Also the number of our patients with EAR, who responded to salvage 
therapy with steroids (75%), is comparable to the results reported previously [42, 44, 50]. 
 
In our cohort no patient died of problems directly related to rejection. Two girls needed a 
second graft because of chronic rejection. This 5.4% incidence of chronic rejection in our 
cohort compares well to the incidences of 2-20% reported in other pediatric studies [1, 17, 42, 
50]. 
The median time of appearance of EAR after LT was 8 days in our cohort. This time is 
confirmed by other authors who observed a median time of more or less one week until the 
first EAR after LT [26, 42, 45, 54, 61].  
 
 
6.2. Patient dependant variables 
 
Age 
Age could have an influence on the risk for EAR, because the immune system is undergoing 
many developmental changes during infancy and childhood. Cell mediated immunity is still 
immature in very young babies and it is known to decrease again with old age  [21, 27]. 
Three studies observed that children under the age of 1 year had a lower incidence of both 
acute and chronic rejection than older recipients. But the children in two of this study groups 
were also rather severely malnourished and about 80% had extrahepatic biliary atresia [6, 25, 
42], two other factors that could also decrease the risk of EAR in these patient groups.   
In our cohort we couldn't confirm this finding. The children with EAR in this study tended to 
be younger than the children without EAR, with 80% rejection in children under 1 year 
compared to 59% rejection in children older than 1 year, but the difference was not 
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statistically significant. Also two other authors reported high EAR rates in their infants who 
had LT during their first year of life, 85% and 64% respectively [16, 56]. 
Whereas Woodle reported an EAR rate of 42% for infants younger than 3 months [63].  
 
The results from adult studies analyzing the influence of age on EAR are also contradictory. 
Some authors found an independent influence of age on rejection with younger patients being 
at greater risk for EAR than older patients [4, 26, 61]. Others found that age had no influence 
on EAR  [8, 54].  
 
The interpretation of these results is difficult, because the analyzed patient groups, especially 
for children younger than 1 year are all very small. Additionally the data come from different 
time periods over the last 20 years and are certainly influenced by a changing selection of the 
patients and the ongoing development of surgical and immunosuppressive therapies.  
Until now no clear influence of age on EAR could be shown neither in pediatric nor in adult 
studies. 
 
 
Gender 
No difference of gender distribution was found in this cohort of patients between the children 
with or without EAR. No other pediatric data are published examining a possible influence of 
gender on EAR. 
 
The results from studies with adult patients are contradictory. Most authors found, that the 
gender of the host had no influence on EAR [4, 8, 26, 54, 61] whereas a higher percentage of 
EAR in female recipients was found only once [11].  
 
 
Blood group 
All the children in this cohort received a graft from a blood group identical donor. The 
number of children with blood group A and O (18/18) was identical, with a preponderance of 
blood group A in group R and O in group NR, but the difference was not statistically 
significant.  
No influence of the blood group on EAR was found in one study with adults [26]. 
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CMV and EBV infection before LT 
Patient with negative CMV- status before LT are at an increased risk of developing CMV 
infection after LT. CMV infection after LT was shown to be associated with more EAR in 
adults, especially with CMV genotype gB1 [52]. Therefore we hypothesized that children 
with negative CMV status before LT could have a higher risk for EAR and more children 
with positive CMV status should be found in group NR. But we could not find an influence in 
our cohort with 54% CMV-IgG pos in group R versus 46% in group NR. The same 
observation was made by two other authors [26, 42].  
Also previous infection with EBV did not have an influence on EAR in this cohort. 
 
 
Underlying liver disease 
The indications for LT in our cohort are comparable to other pediatric studies, with 
extrahepatic biliary atresia being the underlying liver disease in more than 50% of the 
children [1, 17, 30, 42, 53], and metabolic diseases on second place with 21% [34, 42].  
 
Underlying liver disease could be an independent risk factor for the development of EAR. 
Most data regarding influence of underlying liver disease on EAR come from adult studies. 
In a group of 252 adult patients, those with cholestatic disease exhibited a significantly 
increased risk for acute rejection compared with patients with other liver diseases. At 6 
months when 94% of all rejection episodes had occurred, the cumulative rates of acute 
rejection were 0.45 for alcoholic cirrhosis, 0.55 for posthepatitic cirrhosis, 0.65 for hepatoma 
and 1.00 for cholestatic disease. Steroid resistant acute rejection was diagnosed in 12 % of 
patients with cholestatic disease, in 10% with alcoholic cirrhosis, in 6.6% with hepatoma and 
was only significantly lower in posthepatitic cirrhosis with 1.7% [8]. 
In another adult study examining 133 patients, it was shown, that patients with 
immunologically mediated liver disease (eg, autoimmune hepatitis, primary biliary cirrhosis) 
had the highest risk of developing EAR. The adjusted odds ratios compared to alcoholic 
cirrhosis were 16.07 for immunologically mediated liver disease, 12.34 for patients with 
metabolic liver disease, 3.13 for HCV and 1.62 for HBV cirrhosis [26]. Similar findings were 
published by Neuberger et al who also found the highest risk for EAR for patients with 
autoimmune and cholestatic liver disease [44, 45].   
Patients with alcoholic liver disease have less EAR than patients with non alcoholic liver 
disease [4]. 
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Overall it seems that cholestatic liver disease is an important risk factor for the development 
of EAR in adult patients. 
 
On the other hand it was shown that cholestasis can suppress the immune system and 
therefore patients with deep jaundice may be protected against graft rejection [3].  
 
In our study more children in group NR had biliary atresia (76.9%) compared with group R 
(58.1%) and the value of direct bilirubin in blood before LT was higher for patients who 
remained free from EAR (246.5µmol/L) compared with the children with subsequent EAR 
(159.6µmol/L), but the difference was not statistically significant (p=0.12). This means that 
our children in contrast to the adult patients showed a tendency to be protected from EAR 
when suffering from cholestasis due to EHBA.   
This could be explained by the fact that EHBA, to our knowledge is not caused by  
immunological mechanism, whereas most cholestatic disorders in adults are of autoimmune 
origin .The autoimmune mechanism could have a strong pro-rejection effect, overwhelming 
the potentially protective effect of cholestasis. Other factors protecting from rejection in this 
group of children with EHBA could be the fact that they tend to be more malnourished at the 
time of transplantation, showing a tendency to have lower z-scores for height and weight than 
the children with other liver diseases. 
Other data from pediatric patients are rare, only one other pediatric study looked for the 
influence of underlying liver disease on EAR, but could find none [42].  
 
 
Nutritional status 
Inadequate intake of nutrients is a very common problem in children with liver disease and 
malnutrition often worsens with the progression of the disease. Especially infants are at an 
increased risk for malnutrition and it was shown that they were smaller and more 
malnourished at LT than those who received transplants at an older age [30].  
But not only age, also the origin and stage of the underlying liver disease have an influence on 
the development of malnutrition. Compared with metabolic causes of end stage liver disease 
and fulminant hepatic failure, children with EHBA were more malnourished and delayed in 
growth at LT and the most malnourished and growth impaired were those with Alagille 
syndrome [30]. 
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Also in this cohort, despite intensive nutritional care, most children were malnourished. 83% 
of all children had a negative z-score for their weight and 73% a negative z-score for height. 
But in contrast to the study mentioned above, we could not find a significant difference of 
malnutrition between younger and older children, nor between children with EHBA and other 
liver diseases. This difference could possibly be explained by the fact that the infants in this 
cohort, most of them suffering from EHBA, received an intensive nutritional support with 
nasogastric feeding more often than older children suffering from other hepatic disorders. 
 
It is well known that malnutrition in general adversely affects many aspects of immune 
function, especially the cell mediated immune response which is crucial in organ rejection.  
It was observed that malnutrition in end stage liver disease can lead to impaired cell mediated 
immunity [46, 40], and that cell mediated reactivity is directly related to severity of liver 
disease [38, 64].  
Patients with a Child A stage of their liver disease (good hepatic function)and better physical 
condition had a 5 times higher risk for EAR than patients with Child B or C [26].  
This finding was confirmed by an other author who found that patients with Child score A 
and normal mid-arm circumference had a higher risk for EAR, with mid-arm circumference 
being the only factor independently associated with EAR [4]. In a third study no influence of 
Child score and nutritional status on EAR was observed [61].  
 
In our cohort of children we could find a statistically significant influence of the nutritional 
status on EAR. Children with low z-scores for weight and height had significantly less EAR 
than children with higher z-scores. Median z-score for weight was -2.3 for group NR versus  
-0.8 for group R (p=0.02) and median z-score for height was -2.15 in group NR versus -0.9 in 
group R (p=0.02). 
In another pediatric study, children with lower height z-score had less EAR, but the difference 
was not statistically significant, with a z-score of -1.6 for group NR versus -0.5 for group R 
[42].  
In summary, there seems to be some evidence that malnutrition could be associated with a 
lower risk for EAR in children and adults. Since malnourished individuals have a higher risk 
for infection and a lethal outcome after LT, it would be worthwhile to consider a less 
aggressive immunosuppressive therapy for malnourished patients compared with patients in 
good nutritional condition. 
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White blood cell count 
Cell mediated immune mechanisms are responsible for graft rejection after transplantation.  
T-lymphocytes are known to have the most important effect on the development of rejection.  
But also eosinophils are a specific feature of acute rejection in adults as shown by different 
groups [ 7, 19, 24, 43 ] and may be elevated in blood or portal tracts as a very early sign of 
EAR. Dollinger et al reported a significantly higher pretransplant eosinophil blood count  in 
patient who developed rejection within 11 days posttransplant. After the beginning of 
immunosuppression the eosinophils dropped to low levels for all patients, but a significant 
rise was observed again in patients who developed rejection with a maximum at day 7 post 
LT [20] 
In this study we wanted to know whether the number of all white blood cells (WBC), 
eosinophils and lymphocytes immediately before LT could be used as a predictive factor for 
the risk of EAR. 
The number of WBC was significantly lower in the group of children who did not develop 
EAR compared with the children with EAR. But this variable was directly related to lower z-
scores for weight and height in logistic regression analysis. It remains therefore unclear 
whether  lower leucocytes before LT are an epi-phenomenon of malnutrition or whether they 
have a direct influence on the development of EAR. In another adult study no influence of the 
leucocyte count before LT on EAR could be observed [4]. 
Looking at the eosinophil and lymphocyte blood counts before LT in our cohort, we could 
observe a trend of lower values in patients who did not develop EAR, but the difference was 
not statistically significant.  
 
 
Liver tests before LT 
One adult study examined AST blood levels before LT and found that patients with elevated 
AST levels had a significantly higher rate of EAR than patients with lower levels [61]. But it 
was not shown whether pre-LT AST levels were correlated with other factors like underlying 
liver disorder or stage of disease. 
In our cohort we could not find a difference in the pre-LT levels for AST, ALT, GGT, total 
and direct bilirubin comparing group R and NR. Group NR showed a trend for higher levels 
of direct bilirubin in correlation with the higher number of children with EHBA in this group, 
but the difference was not significant with a p-value of  0.12. 
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6.3. Donor dependant variables 
 
Age 
The results of the influence of the donor’s age on EAR in adult studies are very contradictory. 
One author found no influence [26]. One author found that patients receiving liver grafts from 
donors between 30 and 50 years old had a lower risk for EAR than those receiving grafts from 
donors younger than 30 or older than 50 years [4]. But this finding was contradicted by 
another study where the highest risk for EAR was found for patients receiving a graft from 
donors between 30 and 40 years old [61].  
In our pediatric cohort, the median age of the donors was much lower compared to adult 
studies, with a median age of 17 years (0.6 – 55y). There was no difference of donor age 
between group R and NR. 
 
Gender 
75% of the donors were males, reflecting the higher death rate due to accidents in the group of 
male children and young adults, compared to females. 
Comparing gender matching between male and female hosts and donors, no influence was 
found in our cohort, but the numbers are too small for a reasonable statistical analysis. 
In one adult study an increased incidence of chronic rejection was found for the combination 
of male donor and female recipient [15], but two other authors described that the gender of 
the donor had no influence on EAR [ 26, 61].  
 
 
CMV infection 
Positive donor CMV IgG status is a major risk factor for liver allograft recipient infection 
[47].  CMV infection after LT was suspected to be a possible risk factor for EAR [51] and 
chronic rejection later on [29].   
Therefore hosts receiving grafts from CMV-IgG antibody positive donors are at a greater risk 
to develop CMV infection after LT than hosts receiving grafts from CMV negative donors 
and could theoretically also have a higher risk to develop EAR.  
This hypothesis could not be proved with our data, where more CMV pos donors were found 
for patients in group NR, 9 of 13 patients ( = 69%), compared to 10/23 ( = 43% ) in group R, 
but the results were not different with a p-value of  0.13. There remains a weak point for final 
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interpretation, because the incidence of CMV infection after LT was not analyzed in this 
study.  
Only one other study looked for an influence of previous CMV infection of the donor on 
EAR, but could not find a difference either [26]. 
 
 
 
6.4.  Liver size and graft injury  
 
Liver size 
The large mass of  donor antigen with LT may lead to overstimulation and exhaustion of the 
recipient´s immune response and could explain the relative resistance of the liver to rejection 
compared with other organs [ 9, 10, 58].  
Among recipients of liver grafts there is little data to show whether the amount of grafted 
liver has an influence on EAR. 
In our group of patients only 10 of 37 children received a whole liver graft. 27 children 
needed a reduced-size liver because of graft-recipient mismatch. 24 received a left liver lobe 
and 3 a 1 or 2 liver segment split. There was no difference between the two groups R and NR 
regarding size of the graft. This fits well with an other observation where the authors initially 
found a higher EAR rate after reduced liver transplantation in children, but when they 
corrected the two groups (full versus reduced LT) for body weight the difference was not 
more present [13]. 
 
 
Graft injury 
Graft injury may be caused by a long ischemia time or through manipulation during graft 
reduction. It has been suggested that graft injury before LT may lead to antigen shedding from 
necrotic cells, especially endothelial cells, at the time of transplantation and may initiate a 
cascade of immunologic events resulting in cellular rejection of the graft [14, 31, 49, 60, 62]. 
It was observed that high transaminase levels within 72 hours after LT may reflect 
preservation injury [ 36, 51], an early rise of transaminase levels could therefore be prognostic 
for EAR. 
There was no influence of cold and warm ischemia time or transaminase peak levels within 
72 hours after LT on EAR in our cohort of patients. Also other authors were unable to 
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correlate frequency of acute rejection with cold ischemia time or evidence of preservation 
injury on liver biopsy [1, 4, 8, 26, 35]. 
 
 
 
6.5. Risk score for EAR 
Few risk models for EAR were calculated for adult patients. Gomez-Manero [26] described a 
risk model for 133 patients, were recipients age, underlying liver disease and Childs class 
score were independently associated with EAR in multivariate analysis: EAR score [F(x)]= 
2.44 + (1.14 x hepatitis C virus cirrhosis) + (2.78 x immunologic cirrhosis) + (2.51 x 
metabolic cirrhosis) – (0.08 x recipient’s age in years) + (1.65 x Child’s class), risk for 
rejection = e(F(x))/1 + e(F(x)). 
With the aim to obtain an easily usable risk estimation, we decided to take the statistical 
model of a classification tree. With this model we could show that two groups of children 
have a very high risk for EAR of above 90% whereas other groups have a much lower risk of 
only around 20%. 
Children with a high risk of EAR are all children with a z-score for height above -1.1 and 
children with a z-score below -1.1 and an age at LT below 17.5m and GGT serum values 
below 200 IU/L. 
Children with a low risk of EAR are children with a z-score for height below -1.1 and age at 
LT below 17.5m, but GGT serum value above 200 IU/L and children with a z-score below -
1.1. and age at LT above 17.5m.  
Clinically spoken this means that children with severe underweight, age below 18months and 
high GGT values (mostly due to EHBA) have a relatively low risk of EAR of 40%. And the 
lowest risk of only 20% was found for the children with malnutrition and age above 18m. 
This group of children could possibly be treated with less immunosuppressive medication 
than the high risk groups. 
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6.6. Immunosuppressive treatment 
Despite two decades of use, there are still limited data on the best way to monitor CsA for 
liver transplantation. Up to now it is agreed among almost all LT centers to measure CsA 
trough levels and to adjust the CsA dose to reach the target levels. It is also commonly 
accepted that higher CsA doses protect better against EAR than lower doses.  
We expected to find lower CsA levels in children with EAR, suspecting a less efficient 
immunosuppression in this group. 
But comparing the CsA trough levels of ten age and sex matched pairs out of group R and NR 
from the day of LT until diagnosis of rejection, we could not find a difference between the 
two groups. The children with EAR had even slightly higher CsA levels with a median value 
of 246.7µg/L versus 232.1µg/L in group NR, p=0.3.  
This observation is confirmed by Grant et al who found a poor correlation between trough 
CsA levels and graft rejection. But he could show a strong correlation between freedom from 
graft rejection during the first month after LT and (a) the area under the curve (AUC) for the 
first 6 hours after the dosing and (b) the peak CsA levels (Cmax)at days 5 and 10 after LT in 
patients treated with Neoral®. CsA levels 2 hours after dosing closely reflected AUC 0-6 in 
patients treated with Neoral®, whereas there was a poorer correlation in patients on 
Sandimmun® [28]. These findings could be explained by in vitro experiments, showing 
profound inhibition of calcineurin and immune responses when lymphocytes are exposed to 
high peak CsA levels [5].  
Cmin 0 and C max are kept at the same level when patients are on a continuous constant rate 
intravenous infusion of CsA. It has recently been suggested that the induction of 
immunosuppression using Neoral together with a continuous intravenous infusion of CsA 
results in higher rejection rates than induction with Neoral® alone, supporting the hypothesis 
that Cmax may be more important than trough levels for the prevention of liver graft 
rejection[39].  
Our results and these few data from literature suggest that Cmax and/ or AUC 0-6 may provide 
better measures of immune suppression than the usual measurement of trough levels after LT. 
But prospective studies are needed to determine whether a change of  pharmacokinetic 
monitoring of CsA levels will be helpful to further reduce EAR after LT. 
 
Recurrent, late or severe episodes of acute rejection were found to predispose to chronic 
rejection, both in adults and in children [29, 55]. The two girls in this cohort, who developed 
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chronic rejection and therefore needed a second LT, had each two episodes of EAR after LT 
and both were resistant to steroid salvage therapy. 
Whether a better monitoring of immunosuppression as mentioned above will lead to less EAR 
and perhaps also to less chronic rejection remains to be proved. 
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7. Summary 
 
Our group of children, though rather small in number, is comparable regarding survival rate, 
age at LT, underlying liver disease, method of immuno-suppression and incidence of EAR to 
other groups of children from larger centers. This means, that our patients did not undergo a 
special selection and can therefore be compared with the results from other pediatric studies. 
 
Malnutrition, reflected by significantly lower z-scores for weight and height and accompanied 
in this cohort by lower leucocyte counts,  decreased the risk for EAR.  
Children with high direct bilirubin and GGT values in serum before LT, reflecting cirrhosis 
from extrahepatic biliary atresia, showed a trend of having less EAR than children with other 
diseases, but the patient number was probably to small to give a statistically significant result 
in the univariate analysis. 
Estimating the risk for EAR with the three variables z-score for height, age at transplantation 
and GGT serum values before LT in a classification tree, we could show that children with a 
z-score for height below -1.1, age at LT below 18months and GGT values above 200 IU/L 
(mostly due to EHBA) have a relatively low risk of EAR of 40%. And the lowest risk for 
EAR of only 20% was found for the children with a z-score for height below -1.1 and age 
above 18m.  
Because individuals with malnutrition have an elevated risk for a lethal outcome after LT, 
mainly as a consequence of infectious complications, and they seem to have a lower risk for 
developing EAR, these patients could probably benefit from less aggressive immuno-
suppressive therapy. 
 
Immunosuppression monitored with CsA trough levels had no influence on the prevention of 
EAR. There was no difference of daily mean CsA trough levels between children with and 
without EAR from LT until the first day of EAR. This finding supports the results from 
pharmacokinetic studies with CsA, which showed a poor correlation of CsA trough levels 
with graft rejection, but a strong correlation between freedom from EAR with both, the area 
under the curve for the first 6 hours after the dosing and the peak CsA levels (Cmax) at days 5 
and 10 after LT. It seems that the CsA peak level is more relevant for the prevention of 
rejection, than the CsA trough level. With this results in mind the method of CsA monitoring 
should probably be changed in future, replacing the monitoring of CsA trough levels with the 
monitoring of the area under the curve of CsA and/ or its peak levels. 
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List of abbreviations (in alphabetic order) 
 
ALT   Alanine- Aminotransferase 
AST   Aspartate-Aminotransferase 
ATG   Antithymocyte Globuline 
CMV   Cytomegalo virus 
CsA   Cyclosporine A 
EAR   Early acute rejection 
EBV   Ebstein Barr virus 
EHBA   Extrahepatic biliary atresia 
GGT   Gamma-Glutamyltransferase 
HLA-DR  Human leucocyte antigen 
IgG-Ab  Immunoglobuline G antibodies 
LT   Liver transplantation 
OKT 3   Monoclonal antibody binding to the ε chain of the CD3 receptor 
PFIC   Progressive familiar intrahepatic cholestasis 
ROC   Receiver operated characteristics 
Sd   Standard deviation 
Tac   Tacrolimus 
WBC   White blood cell count 
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